Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01221844|
Recruitment Status : Completed
First Posted : October 15, 2010
Last Update Posted : June 27, 2011
The purpose of this study is to determine whether bovine lactoferrin is effective in preventing and curing iron deficiency and iron deficiency anemia in Hereditary Thrombophilia affected women during pregnancy.
The proposed clinical trial is considered as PHASE IV because in Italy bLf is commercialized by Grunenthal, as Lattoglobina® (capsules with 100 mg of bLf), to prevent and cure iron deficiency and iron deficiency anemia in pregnant women.
|Condition or disease||Intervention/treatment||Phase|
|Pregnancy Iron Deficiency Iron Deficiency Anemia||Dietary Supplement: Lattoglobina (Grunenthal) containing bLf Drug: FerroGrad by Abbott||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||March 2011|
|Actual Study Completion Date :||May 2011|
Experimental: Lactoferrin treatment in HT pregnacies
Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
Dietary Supplement: Lattoglobina (Grunenthal) containing bLf
One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
Active Comparator: Ferrous sulfate in HT pregnancies
Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.
Drug: FerroGrad by Abbott
Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
- Hematological parameters [ Time Frame: At time 0 (enrollement) and every 30 days until delivery (6-8 months) ]Efficacy of bLf versus ferrous sulfate in preventing and curing iron deficiency and iron deficiency anemia
- Side effects [ Time Frame: 6-8 months ]
Control of side effects of oral administration of bLf and ferrous sulfate as:
- gastrointestinal discomfort
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01221844
|Clinica Fabia Mater|
|Rome, Rm, Italy|
|Study Chair:||Rosalba Paesano, Dr||Clinica Fabia Mater, Via Olevano Romano 25, Rome (Italy)|